Company profile HRTX
After 38 days of this quarter the interest is at 44.0. Based on that we can calculate that during remaining 53 days it will total up to 105.0. That appears to be equal to previous quarter and same quarter last year.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 123 | 243 97.6% QoQ | 183 -24.7% QoQ | 154 -15.8% QoQ |
| 2020 | 141 14.6% YoY -8.4% QoQ | 362 49.0% YoY 156.7% QoQ | 155 -15.3% YoY -57.2% QoQ | 88 -42.9% YoY -43.2% QoQ |
| 2021 | 92 -34.8% YoY 4.5% QoQ | 207 -42.8% YoY 125.0% QoQ | 103 -33.5% YoY -50.2% QoQ | 134 52.3% YoY 30.1% QoQ |
| 2022 | 152 65.2% YoY 13.4% QoQ | 87 -58.0% YoY -42.8% QoQ | 154 49.5% YoY 77.0% QoQ | 91 -32.1% YoY -40.9% QoQ |
| 2023 | 123 -19.1% YoY 35.2% QoQ | 96 10.3% YoY -22.0% QoQ | 103 -33.1% YoY 7.3% QoQ | 126 38.5% YoY 22.3% QoQ |
| 2024 | 44 -64.2% YoY -65.1% QoQ | - | - | - |
The average 5 years interest of Heron Therapeutics was 11.39 per week. The last year interest of Heron Therapeutics compared to the last 5 years has changed by -22.83%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -39.04%.
There is not enough data for Heron Therapeutics products to provide analysis
There is not enough data for Heron Therapeutics products to provide correlation calculation
There is not enough data for Heron Therapeutics products to provide analysis
After 38 days of this quarter the interest is at 69.0. Based on that we can calculate that during remaining 53 days it will total up to 165.0. Heron Therapeutics stock expected interest is significantly higher compared to same quarter last year (+44.7%) but similar to previous quarter.
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2019 | 144 | 154 6.9% QoQ | 171 11.0% QoQ | 140 -18.1% QoQ |
| 2020 | 199 38.2% YoY 42.1% QoQ | 558 262.3% YoY 180.4% QoQ | 262 53.2% YoY -53.0% QoQ | 190 35.7% YoY -27.5% QoQ |
| 2021 | 192 -3.5% YoY 1.1% QoQ | 301 -46.1% YoY 56.8% QoQ | 85 -67.6% YoY -71.8% QoQ | 125 -34.2% YoY 47.1% QoQ |
| 2022 | 280 45.8% YoY 124.0% QoQ | 141 -53.2% YoY -49.6% QoQ | 163 91.8% YoY 15.6% QoQ | 104 -16.8% YoY -36.2% QoQ |
| 2023 | 114 -59.3% YoY 9.6% QoQ | 58 -58.9% YoY -49.1% QoQ | 118 -27.6% YoY 103.4% QoQ | 187 79.8% YoY 58.5% QoQ |
| 2024 | 69 -39.5% YoY -63.1% QoQ | - | - | - |
The average 5 years interest of Heron Therapeutics stock was 14.44 per week. The last year interest of Heron Therapeutics stock compared to the last 5 years has changed by -28.88%. This is something to be checked. The last year interest is quite lower compared to 5 years ago. It has decreased by -24.87%.
There is not enough data for bupivacaine meloxicam to provide analysis
There is not enough data for bupivacaine meloxicam to provide correlation calculation
There is not enough data for bupivacaine meloxicam to provide analysis
There is not enough data for SUSTOL injection to provide analysis
There is not enough data for SUSTOL injection to provide correlation calculation
There is not enough data for SUSTOL injection to provide analysis
There is not enough data for CINVANTI intravenous formulation to provide analysis
There is not enough data for CINVANTI intravenous formulation to provide correlation calculation
There is not enough data for CINVANTI intravenous formulation to provide analysis
There is not enough data for HTX-019 postoperative nausea and vomiting to provide analysis
There is not enough data for HTX-019 postoperative nausea and vomiting to provide correlation calculation
There is not enough data for HTX-019 postoperative nausea and vomiting to provide analysis
There is not enough data for HTX-034 postoperative pain management to provide analysis
There is not enough data for HTX-034 postoperative pain management to provide correlation calculation
There is not enough data for HTX-034 postoperative pain management to provide analysis
There is not enough data for Heron Therapeutics address to provide analysis
There is not enough data for Heron Therapeutics address to provide correlation calculation
There is not enough data for Heron Therapeutics address to provide analysis